카디프 종양학, Inc.
DE ˙ DB ˙ US14147L1089
€1.13 ↓ -0.10 (-7.78%)
2026-06-04
주가
SecurityDE:XE7C / Cardiff Oncology, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership400,576 shares
Latest Disclosed Value $ 648,934
UBS Group AG ownership in XE7C / Cardiff Oncology, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 400,576 shares of Cardiff Oncology, Inc. (DE:XE7C) valued at $524,755 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 87,429 shares of Cardiff Oncology, Inc.. This represents a change in shares of 358.17% during the quarter. The current value of the position is $592,452 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (XE7C) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:XE7C / Cardiff Oncology, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F CARDIFF ONCOLOGY COM 14147L108 400,576 313,147 358.17 649 164.49 0.0001
2026-01-29 2025-12-31 13F CARDIFF ONCOLOGY COM 14147L108 87,429 -118,746 -57.59 246 -42.22 0.0000
2025-11-13 2025-09-30 13F CARDIFF ONCOLOGY COM 14147L108 206,175 8,737 4.43 425 -31.72 0.0001
2025-08-14 2025-06-30 13F CARDIFF ONCOLOGY COM 14147L108 197,438 110,903 128.16 622 129.15 0.0001
2025-05-13 2025-03-31 13F CARDIFF ONCOLOGY COM 14147L108 86,535 -196,817 -69.46 272 -77.95 0.0000
2025-02-14 2024-12-31 13F CARDIFF ONCOLOGY COM 14147L108 283,352 234,788 483.46 1,230 852.71 0.0002
2024-11-14 2024-09-30 13F CARDIFF ONCOLOGY COM 14147L108 48,564 6,599 15.73 130 38.71 0.0000
2024-08-14 2024-06-30 13F CARDIFF ONCOLOGY COM 14147L108 41,965 39,003 1,316.78 93 520.00 0.0000
2024-05-13 2024-03-31 13F CARDIFF ONCOLOGY COM 14147L108 2,962 -393 -11.71 16 275.00 0.0000
2024-02-09 2023-12-31 13F CARDIFF ONCOLOGY COM 14147L108 3,355 3,292 5,225.40 5 0.0000
2023-11-09 2023-09-30 13F CARDIFF ONCOLOGY COM 14147L108 63 -3,751 -98.35 0 -100.00 0.0000
2023-08-11 2023-06-30 13F CARDIFF ONCOLOGY COM 14147L108 3,814 -11,876 -75.69 6 -80.00 0.0000
2023-05-12 2023-03-31 13F CARDIFF ONCOLOGY COM 14147L108 15,690 10,005 175.99 26 257.14 0.0000
2023-02-08 2022-12-31 13F CARDIFF ONCOLOGY COM 14147L108 5,685 -2,760 -32.68 8 -46.15 0.0000
2022-11-10 2022-09-30 13F CARDIFF ONCOLOGY COM 14147L108 8,445 8,403 20,007.14 13 0.0000
2022-08-10 2022-06-30 13F CARDIFF ONCOLOGY COM 14147L108 42 -6,942 -99.40 0 -100.00
2022-05-16 2022-03-31 13F CARDIFF ONCOLOGY COM 14147L108 6,984 -5,080 -42.11 17 -76.39 0.0000
2022-02-14 2021-12-31 13F CARDIFF ONCOLOGY COM 14147L108 12,064 8,704 259.05 72 227.27 0.0000
2021-11-15 2021-09-30 13F CARDIFF ONCOLOGY COM 14147L108 3,360 3,360 22 0.0000
2021-05-12 2021-03-31 13F CARDIFF ONCOLOGY COM 14147L108 0 -634 -100.00 0 -100.00
2021-02-11 2020-12-31 13F CARDIFF ONCOLOGY COM 14147L108 634 -3,145 -83.22 11 -79.25 0.0000
2020-11-12 2020-09-30 13F CARDIFF ONCOLOGY COM 14147L108 3,779 -743 -16.43 53 130.43 0.0000
2020-07-31 2020-06-30 13F CARDIFF ONCOLOGY COM 14147L108 4,522 4,522 23 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-01-29 2025-12-31 13F CARDIFF ONCOLOGY COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-13 2025-09-30 13F CARDIFF ONCOLOGY COM Call 633,000 0.00 1,304 -34.62 n/a n/a n/a
2025-08-14 2025-06-30 13F CARDIFF ONCOLOGY COM Call 633,000 0.00 1,994 0.30 n/a n/a n/a
2025-05-13 2025-03-31 13F CARDIFF ONCOLOGY COM Call 633,000 0.00 1,988 -27.67 n/a n/a n/a
2025-02-14 2024-12-31 13F CARDIFF ONCOLOGY COM Call 633,000 0.00 2,747 62.54 n/a n/a n/a
2024-11-14 2024-09-30 13F CARDIFF ONCOLOGY COM Call 633,000 0.00 1,690 20.28 n/a n/a n/a
2024-08-14 2024-06-30 13F CARDIFF ONCOLOGY COM Call 633,000 0.00 1,405 -58.43 n/a n/a n/a
2024-05-13 2024-03-31 13F CARDIFF ONCOLOGY COM Call 633,000 3,380 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-05-13 2025-03-31 13F CARDIFF ONCOLOGY COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-14 2024-12-31 13F CARDIFF ONCOLOGY COM Put 30,000 130 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.